{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-091744","form_type":"8-K","ticker":"RANI","cik":"0001856725","company_name":"Rani Therapeutics Holdings, Inc.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.970573+00:00","generated_at":"2026-05-31T12:39:21.852769+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Rani Therapeutics posts Q2 net loss of $13.4M; announces ProGen partnership for oral obesity drug RT-114","bullets":["Cash, equivalents and marketable securities totaled $30.9M as of June 30, 2024, down from $48.5M at Dec. 31, 2023.","Net loss of $13.4M for Q2 2024, compared to $18.7M in same period 2023; includes $4.1M stock-based compensation.","R&D expenses fell to $6.1M from $11.1M YoY, driven by workforce reduction and timing of preclinical/clinical studies.","Announced co-development partnership with ProGen for RT-114, an oral GLP-1/GLP-2 dual agonist, with 50/50 cost and revenue share.","Phase 1 study for RT-114 expected to start in 2025; completed $10.0M equity offering in July 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-091744","json":"https://secwatch.observer/filing/0000950170-24-091744.json","markdown":"https://secwatch.observer/filing/0000950170-24-091744.md","text":"https://secwatch.observer/filing/0000950170-24-091744.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1856725/000095017024091744/0000950170-24-091744-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1856725/000095017024091744/rani-20240806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:39:21.852769+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}